Previously in the ARCHIVES, we reported a case of late recurring Wegener granulomatosis (WG) that was successfully treated with combination therapy consisting of cyclophosphamide and cyclosporin.1 The 36-year-old woman, whose WG recurred 18 years after her first remission with cyclophosphamide and corticosteroid therapy, was treated with cyclosporin and prednisolone after undergoing a resection of corneal granuloma. However, because of severe tracheal stenosis with subglottic granuloma, cyclophosphamide was added to her treatment regimen, and with the combination therapy of cyclophosphamide, cyclosporin, and prednisolone, her condition improved rapidly. Cyclophosphamide therapy was discontinued in January 2000 (8 months after the initiation), because of the patient's clinical stability and her rejection of cyclophosphamide therapy. In October 2000, she was referred to our clinic with hematuria, and subsequent evaluation resulted in a diagnosis of urinary bladder cancer. The patient underwent total cystectomy in February 2001. The treatment for this refractory and clinical malignant disease is difficult, and to date, cyclophosphamide is the most reliable agent against WG. However, considering that WG often affects middle-aged patients2 and that cyclophosphamide has a variety of acute and chronic complications, cyclophosphamide therapy is not recommended for all patients with WG. We report here a second patient with recurrent WG (after spontaneous abortion) who was successfully treated with cyclosporin.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.